Difference between revisions of "Lifileuecel (Contego)"
Jump to navigation
Jump to search
m |
m |
||
| Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/lifileucel NCI Drug Dictionary]: A preparation of autologous tumor infiltrating lymphocytes (TILs), with potential antineoplastic activity. TILs are isolated from a patient's tumor tissue, cultured in vitro with high-dose interleukin-2 (lL-2), further selected based on antigen specificity and tumor reactivity, and the selected TILs are subsequently expanded. Upon re-introduction of lifileucel into the patient, the TILs re-infiltrate the tumor, specifically recognize the tumor-associated antigens (TAAs), and initiate tumor cell lysis. IL-2 induces the proliferation and expansion of TILs in vitro. | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/lifileucel NCI Drug Dictionary]: A preparation of autologous tumor infiltrating lymphocytes (TILs), with potential antineoplastic activity. TILs are isolated from a patient's tumor tissue, cultured in vitro with high-dose interleukin-2 (lL-2), further selected based on antigen specificity and tumor reactivity, and the selected TILs are subsequently expanded. Upon re-introduction of lifileucel into the patient, the TILs re-infiltrate the tumor, specifically recognize the tumor-associated antigens (TAAs), and initiate tumor cell lysis. IL-2 induces the proliferation and expansion of TILs in vitro. | ||
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *[[Melanoma]] | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | *'''2024-02-16:''' Granted accelerated approval for adult patients with unresectable or metastatic [[melanoma]] previously treated with a PD-1 blocking antibody, and if BRAF V600 positive, a BRAF inhibitor with or without a MEK inhibitor. | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' LN-144 | *'''Code name:''' LN-144 | ||
| − | *'''Brand name:''' Contego | + | *'''Brand name:''' Amtagvi, Contego |
[[Category:Drugs]] | [[Category:Drugs]] | ||
| Line 10: | Line 16: | ||
[[Category:Tumor infiltrating lymphocytes]] | [[Category:Tumor infiltrating lymphocytes]] | ||
| − | [[Category:Melanoma medications | + | [[Category:Melanoma medications]] |
| − | [[Category: | + | [[Category:FDA approved in 2024]] |
Revision as of 21:36, 19 February 2024
Mechanism of action
From the NCI Drug Dictionary: A preparation of autologous tumor infiltrating lymphocytes (TILs), with potential antineoplastic activity. TILs are isolated from a patient's tumor tissue, cultured in vitro with high-dose interleukin-2 (lL-2), further selected based on antigen specificity and tumor reactivity, and the selected TILs are subsequently expanded. Upon re-introduction of lifileucel into the patient, the TILs re-infiltrate the tumor, specifically recognize the tumor-associated antigens (TAAs), and initiate tumor cell lysis. IL-2 induces the proliferation and expansion of TILs in vitro.
Diseases for which it is used
History of changes in FDA indication
- 2024-02-16: Granted accelerated approval for adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 positive, a BRAF inhibitor with or without a MEK inhibitor.
Also known as
- Code name: LN-144
- Brand name: Amtagvi, Contego